AV-101: A New Generation of Investigational Medicines in Neuropsychiatry and Neurology Known as NMDA Glutamate Receptor Modulators - Global Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "AV-101 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA (N-methyl-D-aspartate) glutamate receptor modulators.

AV-101 is an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), which binds uniquely at the glycine site of the NMDA receptor and has potential to be a new treatment for multiple CNS indications involving NMDA receptors, each with high unmet need. AV-101 is currently in Phase II of clinical trial study for Major Depressive Disorder.

"AV-101 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Major Depressive Disorder in 7 Major Markets. A detailed picture of the AV-101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Scope of the Report

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AV-101.
• The report contains forecasted sales for AV-101 till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Major Depressive Disorder.
• The report also features the SWOT analysis with analyst insights and key findings of AV-101.

AV-101 Analytical Perspective

In-depth AV-101 Market Assessment

This report provides a detailed market assessment of AV-101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

AV-101 Clinical Assessment

The report provides the clinical trials information of AV-101 covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Major Depressive Disorder is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence AV-101 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Major Depressive Disorder are giving market competition to AV-101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of AV-101.
• This in-depth analysis of the forecasted sales data of AV-101 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AV-101.

Key Questions Answered

• Which company is developing AV-101 along with the phase of the clinical study?
• What is the technology utilized in the development of AV-101?
• What is the product type, route of administration and mechanism of action of AV-101?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AV-101 development?
• What are the key designations that have been granted to AV-101?
• What is the forecasted market scenario of AV-101?
• What is the history of AV-101 and what is its future?
• What is the forecasted sales of AV-101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to AV-101?
• Which are the late-stage emerging therapies under development for the treatment of the Major Depressive Disorder?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/fnm6jd